HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting.
PMID: 31117863
2019
Journal of the International Association of Providers of AIDS Care
Table: Y318F
Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.
Method: Resistance mutations in the connection and RNAse H domains of RT spanning amino acids 320-560 included Y318F (3%) and N348I (14%).
Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
Result: Most of the minority mutations in viruses from both groups of naive patients were observed in the RT, e.g., M41L, E44D, A62V, K65R, D67N, D67G, V75I, L100I, K103N, K103R, V188I, M184I, L210W, K219Q, Y318F, etc., although a number of minority mutations associated with resistance to PI (L10F, V11I, M46I/
HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naive and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
Discussion: Previously reported NNRTIs mutations for the 2004 to 2005 period in ARV drug-experienced subjects exposed to AZT or d4T + 3TC or ddI + EFV or NFV or IDV reported K103N at a lower frequency (4.9%), together with mutations L100I (1.2%) and Y318F (1.2%).
HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.
Transmitted drug resistance to rilpivirine among antiretroviral-naive patients living with HIV from northern Poland.
PMID: 24746180
2014
Journal of the International AIDS Society
Result: In one sequence, the Y318F mutation was found.
Discussion: It should be observed that prevalence of the RPV key drug resistance mutations in our sample is higher than that of the K103N mutation, observed in 2.1% of cases, while etravirine resistance-associated mutations were rare (one sequence each with K238T and Y318F).
Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.
Introduction: The recent OPTIMA trial also identified CN mutations Y318F, G333D/E, G335D, N348I, V365I, A371V and A376S as positively associated with treatment experience in a 345 subtype-B-infected patient cohort.
Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity.
PMID: 22828721
2012
Journal of acquired immune deficiency syndromes (1999)
Abstract: Detected CD mutations were G335D (82.3%), A371V (69.8%), E399D (9.4%), N348I (5.2%), V365I (4.2), Y318F (2.1%), G333E (2.1%), and A360V (2.1%).
Method: The CD mutations considered were E312Q, Y318F, G333D/E, G335C/D, N348I, A360I, A360V, V365I, A371V, A376S, and E399G.
Comparative evaluation of the ViroSeq HIV-1 genotyping system and an in-house method for analysis of HIV-1 drug-resistance mutations in China.
Abstract: One NNRTI mutation (the RT mutation Y318F) was reported only by the ViroSeqassay, and this discrepancy resulted from the difference in the pol gene lengths generated by the two systems.
HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
HIV mutation literature information.
PMID: 
2019
Journal of the International Association of Providers of AIDS Care
Browser Board
Co-occurred Entities
Filtrator
ViMRT